+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hospital Infection Therapeutics Market - Global Forecast 2026-2032- Product Image
Hospital Infection Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Hospital Infection Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4905131
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hospital Infection Therapeutics Market is projected to reach USD 11.51 Billion in 2026. It is expected to continue growing at a CAGR of 5.43%, reaching USD 15.85 Billion by 2032.

Hospital infection therapeutics are shifting from reactive treatment toward evidence-led infection prevention, rapid diagnosis, antimicrobial stewardship, and targeted therapy. The clinical need remains substantial: the CDC reports that on any given day about 1 in 31 U.S. hospital patients has at least one healthcare-associated infection, while the WHO identifies antimicrobial resistance as one of the top global public health and development threats.

For care providers, the opportunity is tied to reducing bloodstream infections, surgical site infections, ventilator-associated pneumonia, catheter-associated urinary tract infections, and Clostridioides difficile infection. Hospitals increasingly need therapeutics and protocols that improve patient outcomes, limit avoidable complications, and protect antibiotic effectiveness through responsible use.

Transformative Shifts in the Hospital Infection Landscape

The hospital infection therapeutics landscape is being reshaped by antimicrobial resistance, aging inpatient populations, higher acuity care, invasive procedures, and stricter infection-control standards. The 2019 Global Burden of Disease analysis estimated 1.27 million deaths directly attributable to bacterial antimicrobial resistance and 4.95 million deaths associated with bacterial antimicrobial resistance, reinforcing the clinical urgency behind improved hospital infection management.

Providers are prioritizing pathogen-specific therapy, shorter treatment courses when clinically appropriate, combination regimens for resistant pathogens, and antimicrobial stewardship programs aligned with CDC, WHO, ECDC, and national guidelines. Purchasing decisions increasingly weigh real-world effectiveness, resistance impact, formulary value, diagnostic compatibility, safety profile, and infection-control performance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating hospital infection therapeutics by improving early risk detection, diagnostic triage, antimicrobial selection, and surveillance of resistant organisms. AI-enabled models can analyze microbiology, pharmacy, electronic health record, imaging, and vital-sign data to support earlier intervention in sepsis, bacteremia, pneumonia, and multidrug-resistant infections.

The cumulative impact is operational as well as clinical. When governed carefully, AI can reduce diagnostic delays, flag inappropriate antibiotic use, support stewardship teams, identify infection clusters sooner, and strengthen antimicrobial resistance surveillance. Human clinical oversight remains essential because model bias, data quality, interoperability, and explainability directly affect patient safety and prescribing confidence.

Key Regional Insights

Asia-Pacific is experiencing rising demand for hospital infection therapeutics as large patient volumes, expanding tertiary care, medical technology adoption, and antimicrobial resistance increase treatment complexity. China and India are central to regional demand because of high inpatient volumes and national action plans on antimicrobial resistance, while Japan, South Korea, and Australia are advancing stewardship, hospital quality programs, and infection surveillance. ASEAN hospitals face uneven access to advanced diagnostics and newer antibiotics, making scalable stewardship and affordable therapeutics important regional priorities.

North America remains a strategically important region because of mature antimicrobial stewardship infrastructure, CDC and national surveillance systems, reimbursement scrutiny, and regulatory pathways supporting anti-infective development. Europe emphasizes coordinated resistance monitoring through ECDC-linked systems, strict antimicrobial governance, and health technology assessment discipline. Latin America shows growing need as Mexico and Brazil modernize hospital care while managing healthcare-associated infection risks and antimicrobial access challenges. The Middle East is supported by hospital infrastructure investment, medical tourism, and infection prevention initiatives, particularly in GCC countries. Africa faces a high burden of infectious disease and antimicrobial resistance, with demand shaped by diagnostic access, infection-control capacity, hospital infrastructure gaps, and the need for affordable, effective therapies.

Key Group Insights

ASEAN demand is shaped by dense urban hospitals, variable antimicrobial access, rising healthcare utilization, and the need for scalable stewardship across public and private systems. GCC countries are investing in advanced hospital infrastructure, accreditation, medical tourism, and infection prevention programs, supporting uptake of premium therapeutics, rapid diagnostics, and hospital-based antimicrobial stewardship.

The European Union drives policy-aligned prescribing, cross-border resistance monitoring, procurement discipline, and stewardship standards through coordinated health security and antimicrobial resistance initiatives. BRICS countries represent large-volume clinical need, but successful adoption depends on affordability, local evidence, manufacturing resilience, and alignment with national essential medicine and AMR strategies. G7 markets lead in innovation adoption, reimbursement evidence expectations, surveillance capability, and quality-based hospital procurement, while NATO members increasingly view antimicrobial resilience, supply continuity, and infection preparedness as part of broader health security planning.

Key Country Insights

The United States leads in antimicrobial stewardship implementation, CDC surveillance, hospital quality reporting, and adoption of advanced hospital infection therapeutics, while Canada emphasizes national antimicrobial resistance action, infection prevention, and hospital quality metrics. Mexico and Brazil face high demand for improved infection management as hospital modernization expands across public and private care, with stewardship and diagnostic access remaining key priorities.

The United Kingdom, Germany, France, Italy, and Spain prioritize stewardship, surveillance, antimicrobial prescribing standards, and health technology assessment, supporting evidence-based adoption of hospital infection therapeutics. Russia shows demand linked to hospital capacity, resistant pathogens, and modernization of infectious disease management. China and India are central volume markets due to large inpatient populations and national AMR priorities, Japan and South Korea lead in quality-focused adoption and advanced hospital practice, and Australia combines strict stewardship, infection-control standards, and surveillance-led decision-making to guide therapeutic use.

Actionable Recommendations for Industry Leaders

Hospital leaders should integrate therapeutics, diagnostics, infection prevention, and stewardship rather than treating them as separate purchasing categories. Priority actions include strengthening antibiogram use, aligning empiric therapy with local resistance patterns, deploying rapid diagnostics for high-risk infections, improving source control pathways, and reviewing antibiotic selection and duration through multidisciplinary stewardship teams.

Industry leaders should support hospitals with outcome-based evidence, pharmacoeconomic models, implementation resources, and education aligned with antimicrobial stewardship goals. Products that demonstrate reduced complications, optimized length of stay, fewer readmissions, improved safety, and resistance-conscious use will be better positioned in formularies, clinical pathways, and value-based procurement discussions.

Research Methodology

This executive summary is grounded in secondary research from globally recognized public health and regulatory sources, including WHO, CDC, ECDC, national antimicrobial resistance strategies, peer-reviewed burden-of-disease studies, and hospital infection-control guidance. Insights were assessed for relevance to therapeutics, stewardship, diagnostics, surveillance, procurement, and regional adoption dynamics.

The analysis emphasizes verified epidemiological signals, policy trends, clinical practice shifts, health system behavior, and market-access factors. No unverified market-size, market-share, or forecast claims are used; instead, the summary focuses on evidence-backed demand drivers and strategic implications for stakeholders in hospital infection therapeutics.

Conclusion

Hospital infection therapeutics are becoming a core pillar of patient safety, antimicrobial resilience, and hospital performance. Rising antimicrobial resistance, persistent healthcare-associated infections, and pressure to improve clinical outcomes are driving demand for targeted therapies, rapid diagnostics, surveillance-enabled stewardship, and infection-control aligned care models.

The strongest opportunities will emerge where clinical efficacy, responsible antibiotic use, diagnostic speed, and operational value intersect. Organizations that combine evidence generation, regional understanding, resilient access strategies, and digital decision support will be well positioned to address the next era of hospital infection management.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Hospital Infection Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Antibiotics
7.2.1. Carbapenems
7.2.2. Cephalosporins
7.2.3. Fluoroquinolones
7.2.4. Macrolides
7.2.5. Penicillins
7.3. Antifungals
7.3.1. Azoles
7.3.2. Echinocandins
7.3.3. Polyenes
7.4. Antiseptics
7.4.1. Alcohol Based
7.4.2. Chlorhexidine
7.4.3. Iodophors
7.5. Antivirals
7.5.1. Anti-HBV
7.5.2. Anti-HCV
7.5.3. Anti-HIV
7.5.4. Anti-Influenza
8. Hospital Infection Therapeutics Market, by Route Of Administration
8.1. Introduction
8.2. Inhalation
8.2.1. Nebulized
8.2.2. Dry-Powder
8.3. Oral
8.3.1. Immediate-Release Oral
8.3.2. Modified-Release Oral
8.4. Parenteral
8.4.1. Intramuscular
8.4.2. Intravenous
8.4.3. Subcutaneous
8.5. Topical
9. Hospital Infection Therapeutics Market, by Causative Pathogen Group
9.1. Introduction
9.2. Gram-Positive Bacterial Infection
9.2.1. Staphylococcal Infection
9.2.2. Enterococcal Infection
9.2.3. Streptococcal Infection
9.3. Gram-Negative Bacterial Infection
9.3.1. Enterobacterales Infection
9.3.2. Pseudomonal Infection
9.3.3. Acinetobacter
9.4. Anaerobic Bacterial Infection
9.5. Clostridioides Difficile Infection
9.6. Fungal Infection
9.6.1. Candida Infection
9.6.2. Aspergillus Infection
9.7. Polymicrobial Infection
10. Hospital Infection Therapeutics Market, by Application
10.1. Introduction
10.2. Palliative
10.3. Prophylaxis
10.3.1. Post-Operative
10.3.2. Pre-Operative
10.4. Treatment
10.4.1. Empirical
10.4.2. Targeted Therapy
11. Hospital Infection Therapeutics Market, by End User
11.1. Introduction
11.2. Ambulatory Surgery Centers
11.3. Clinics
11.4. Home Healthcare
11.5. Hospitals
12. Hospital Infection Therapeutics Market, by Primary Treated Infection
12.1. Introduction
12.2. Lower Respiratory Tract Infection
12.3. Bloodstream And Intravascular Infection
12.4. Urinary Tract Infection
12.5. Intra-Abdominal Infection
12.6. Skin, Soft Tissue, And Surgical Wound Infection
12.7. Gastrointestinal Infection
12.8. Bone, Joint, And Device-Associated Infection
12.9. Central Nervous System Infection
12.10. Invasive Fungal Infection
13. Hospital Infection Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
13.5. Wholesalers
14. Hospital Infection Therapeutics Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Hospital Infection Therapeutics Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Hospital Infection Therapeutics Market, by Country
16.1. United States
16.2. China
16.3. Germany
16.4. Japan
16.5. India
16.6. United Kingdom
16.7. France
16.8. Canada
16.9. Australia
16.10. Brazil
16.11. Italy
16.12. Mexico
16.13. South Korea
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Alkem Laboratories Limited
18.2. Allecra Therapeutics GmbH
18.3. Amneal Pharmaceuticals, Inc.
18.4. Antibiotice S.A.
18.5. Astellas Pharma Inc.
18.6. Aurobindo Pharma Limited
18.7. Avenacy Inc.
18.8. Basilea Pharmaceutica Ltd.
18.9. Bayer AG
18.10. Centrient Pharmaceuticals Netherlands B.V.
18.11. Cidara Therapeutics, Inc.
18.12. Cipla Limited
18.13. CSPC Pharmaceutical Group Limited
18.14. Cumberland Pharmaceuticals Inc.
18.15. Dr. Reddy's Laboratories Limited
18.16. Fresenius SE & Co. KGaA
18.17. FUJIFILM Toyama Chemical Co., Ltd.
18.18. Gilead Sciences, Inc.
18.19. GSK plc
18.20. Harbin Pharmaceutical Group Co., Ltd.
18.21. Hikma Pharmaceuticals PLC
18.22. Iterum Therapeutics plc
18.23. JW Pharmaceutical Corporation
18.24. Lupin Limited
18.25. Lyfius Pharma Private Limited
18.26. Melinta Therapeutics, LLC
18.27. Merck & Co., Inc.
18.28. NextPharma Technologies
18.29. North China Pharmaceutical Co., Ltd.
18.30. Orchid Pharma Limited
18.31. Paratek Pharmaceuticals, Inc.
18.32. Pfizer Inc.
18.33. Sandoz Group AG
18.34. SCYNEXIS, Inc.
18.35. Shionogi & Co., Ltd.
18.36. SiNi Pharma Pvt Ltd
18.37. Spero Therapeutics, Inc.
18.38. Sun Pharmaceutical Industries Limited
18.39. Teva Pharmaceutical Industries Ltd.
18.40. USAntibiotics, LLC
18.41. Venatorx Pharmaceuticals, Inc.
18.42. Venus Remedies Limited
18.43. Viatris Inc.
18.44. WG Critical Care, LLC
18.45. Wockhardt Limited
18.46. Xellia Pharmaceuticals ApS
18.47. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CARBAPENEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CARBAPENEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CARBAPENEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL AZOLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ECHINOCANDINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ECHINOCANDINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ECHINOCANDINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL POLYENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ANTISEPTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ANTISEPTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ANTISEPTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ALCOHOL BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ALCOHOL BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ALCOHOL BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CHLORHEXIDINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CHLORHEXIDINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CHLORHEXIDINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL IODOPHORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IODOPHORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IODOPHORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-HBV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-HBV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ANTI-HBV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ANTI-HCV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ANTI-HCV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ANTI-HCV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ANTI-HIV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ANTI-HIV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ANTI-HIV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ANTI-INFLUENZA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ANTI-INFLUENZA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ANTI-INFLUENZA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL INHALATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL NEBULIZED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NEBULIZED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NEBULIZED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL DRY-POWDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL DRY-POWDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL DRY-POWDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL IMMEDIATE-RELEASE ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL IMMEDIATE-RELEASE ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL IMMEDIATE-RELEASE ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL MODIFIED-RELEASE ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL MODIFIED-RELEASE ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL MODIFIED-RELEASE ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL GRAM-POSITIVE BACTERIAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL GRAM-POSITIVE BACTERIAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL GRAM-POSITIVE BACTERIAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL STAPHYLOCOCCAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL STAPHYLOCOCCAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL STAPHYLOCOCCAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ENTEROCOCCAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ENTEROCOCCAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ENTEROCOCCAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL STREPTOCOCCAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL STREPTOCOCCAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL STREPTOCOCCAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL GRAM-NEGATIVE BACTERIAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL GRAM-NEGATIVE BACTERIAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL GRAM-NEGATIVE BACTERIAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ENTEROBACTERALES INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ENTEROBACTERALES INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ENTEROBACTERALES INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PSEUDOMONAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PSEUDOMONAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PSEUDOMONAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ACINETOBACTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ACINETOBACTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ACINETOBACTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ANAEROBIC BACTERIAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ANAEROBIC BACTERIAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ANAEROBIC BACTERIAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL FUNGAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL FUNGAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL FUNGAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL CANDIDA INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL CANDIDA INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL CANDIDA INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL POLYMICROBIAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL POLYMICROBIAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL POLYMICROBIAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL PALLIATIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL PALLIATIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL PALLIATIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL POST-OPERATIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL POST-OPERATIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL POST-OPERATIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL PRE-OPERATIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL PRE-OPERATIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL PRE-OPERATIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL EMPIRICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL EMPIRICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL EMPIRICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL BLOODSTREAM AND INTRAVASCULAR INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL BLOODSTREAM AND INTRAVASCULAR INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL BLOODSTREAM AND INTRAVASCULAR INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL INTRA-ABDOMINAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL INTRA-ABDOMINAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL INTRA-ABDOMINAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL SKIN, SOFT TISSUE, AND SURGICAL WOUND INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 187. GLOBAL SKIN, SOFT TISSUE, AND SURGICAL WOUND INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL SKIN, SOFT TISSUE, AND SURGICAL WOUND INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 189. GLOBAL GASTROINTESTINAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL GASTROINTESTINAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. GLOBAL GASTROINTESTINAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL BONE, JOINT, AND DEVICE-ASSOCIATED INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 193. GLOBAL BONE, JOINT, AND DEVICE-ASSOCIATED INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. GLOBAL BONE, JOINT, AND DEVICE-ASSOCIATED INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 195. GLOBAL CENTRAL NERVOUS SYSTEM INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 196. GLOBAL CENTRAL NERVOUS SYSTEM INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL CENTRAL NERVOUS SYSTEM INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 198. GLOBAL INVASIVE FUNGAL INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 199. GLOBAL INVASIVE FUNGAL INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 200. GLOBAL INVASIVE FUNGAL INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 206. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 208. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 209. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 210. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 211. GLOBAL WHOLESALERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 212. GLOBAL WHOLESALERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. GLOBAL WHOLESALERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 214. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2017-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 221. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 222. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2017-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-POSITIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 227. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-NEGATIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FUNGAL INFECTION, 2017-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2017-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 236. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 237. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 238. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 239. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2017-2032 (USD MILLION)
TABLE 240. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 241. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 243. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 244. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 245. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2017-2032 (USD MILLION)
TABLE 246. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-POSITIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 247. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-NEGATIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 248. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FUNGAL INFECTION, 2017-2032 (USD MILLION)
TABLE 249. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 250. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 251. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 252. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2017-2032 (USD MILLION)
TABLE 254. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 256. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 257. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 258. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 259. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2017-2032 (USD MILLION)
TABLE 260. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 261. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 262. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 263. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 264. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 265. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2017-2032 (USD MILLION)
TABLE 266. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-POSITIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 267. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-NEGATIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 268. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FUNGAL INFECTION, 2017-2032 (USD MILLION)
TABLE 269. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 270. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 271. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 272. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2017-2032 (USD MILLION)
TABLE 274. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 275. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 276. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 277. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 278. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 279. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2017-2032 (USD MILLION)
TABLE 280. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 281. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 283. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 284. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 285. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2017-2032 (USD MILLION)
TABLE 286. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-POSITIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 287. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-NEGATIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 288. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FUNGAL INFECTION, 2017-2032 (USD MILLION)
TABLE 289. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 290. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 291. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 292. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2017-2032 (USD MILLION)
TABLE 294. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 296. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 297. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 298. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 299. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2017-2032 (USD MILLION)
TABLE 300. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 301. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 302. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 303. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 304. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 305. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2017-2032 (USD MILLION)
TABLE 306. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-POSITIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 307. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-NEGATIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 308. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FUNGAL INFECTION, 2017-2032 (USD MILLION)
TABLE 309. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 310. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 311. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 312. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2017-2032 (USD MILLION)
TABLE 314. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 315. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 316. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 317. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 318. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 319. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2017-2032 (USD MILLION)
TABLE 320. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 321. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 322. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 323. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 324. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 325. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2017-2032 (USD MILLION)
TABLE 326. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-POSITIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 327. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-NEGATIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 328. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FUNGAL INFECTION, 2017-2032 (USD MILLION)
TABLE 329. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 330. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 331. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 332. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRIMARY TREATED INFECTION, 2017-2032 (USD MILLION)
TABLE 334. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 335. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 336. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 337. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 338. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 339. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 340. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2017-2032 (USD MILLION)
TABLE 341. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 342. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 343. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 344. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 345. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 346. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CAUSATIVE PATHOGEN GROUP, 2017-2032 (USD MILLION)
TABLE 347. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GRAM-POSITIVE BACTERIAL INFECTION, 2017-2032 (USD MILLION)
TABLE 348. NATO HOSPITAL INFECTION THER

Companies Mentioned

  • Alkem Laboratories Limited
  • Allecra Therapeutics GmbH
  • Amneal Pharmaceuticals, Inc.
  • Antibiotice S.A.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Avenacy Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Centrient Pharmaceuticals Netherlands B.V.
  • Cidara Therapeutics, Inc.
  • Cipla Limited
  • CSPC Pharmaceutical Group Limited
  • Cumberland Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories Limited
  • Fresenius SE & Co. KGaA
  • FUJIFILM Toyama Chemical Co., Ltd.
  • Gilead Sciences, Inc.
  • GSK plc
  • Harbin Pharmaceutical Group Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Iterum Therapeutics plc
  • JW Pharmaceutical Corporation
  • Lupin Limited
  • Lyfius Pharma Private Limited
  • Melinta Therapeutics, LLC
  • Merck & Co., Inc.
  • NextPharma Technologies
  • North China Pharmaceutical Co., Ltd.
  • Orchid Pharma Limited
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sandoz Group AG
  • SCYNEXIS, Inc.
  • Shionogi & Co., Ltd.
  • SiNi Pharma Pvt Ltd
  • Spero Therapeutics, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • USAntibiotics, LLC
  • Venatorx Pharmaceuticals, Inc.
  • Venus Remedies Limited
  • Viatris Inc.
  • WG Critical Care, LLC
  • Wockhardt Limited
  • Xellia Pharmaceuticals ApS
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 11.51 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.85 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned47

Related Topics

Related Reports

Acute Bacterial Skin & Skin Structure Infection Market - Global Forecast 2026-2032 - Product Image

Acute Bacterial Skin & Skin Structure Infection Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Respiratory Tract Infection Therapeutic Market - Global Forecast 2026-2032 - Product Image

Respiratory Tract Infection Therapeutic Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Pneumonia Therapeutics - Global Strategic Business Report - Product Image

Pneumonia Therapeutics - Global Strategic Business Report

  • Report
  • 247 Pages
  • Global
From
MRSA Drugs - Global Strategic Business Report - Product Image

MRSA Drugs - Global Strategic Business Report

  • Report
  • 221 Pages
  • Global
From
Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2026-2034 - Product Image

Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2026-2034

  • Report
  • 141 Pages
  • Global
From

About the Hospital Acquired Infection Drug Market

The Hospital Acquired Infection Drug market is a subset of the Infectious Diseases Drugs market. It focuses on drugs used to treat infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). These drugs are typically antibiotics, antivirals, antifungals, and antiparasitics. They are used to treat infections that are resistant to traditional treatments, or to prevent infections in patients with weakened immune systems. The Hospital Acquired Infection Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Johnson & Johnson, and Bayer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.